Publicacións (94) Publicacións de Antonio Gómez Caamaño

2024

  1. Controversies in prostate cancer management: Consensus recommendations from experts in northern Spain

    Actas Urologicas Espanolas

  2. Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer

    Frontiers in Oncology, Vol. 14

2023

  1. A Biomathematical Model of Tumor Response to Radioimmunotherapy with αpDL1 and αcTLA4

    IEEE/ACM Transactions on Computational Biology and Bioinformatics, Vol. 20, Núm. 2, pp. 808-821

  2. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants

    Nature Genetics, Vol. 55, Núm. 12, pp. 2065-2074

  3. Comparing symptom reporting by prostate cancer patients and healthcare professionals in the international multicentre REQUITE study

    Radiotherapy and Oncology, Vol. 178

  4. Large-scale meta-genome-wide association study reveals common genetic factors linked to radiation-induced acute toxicities across cancer types

    JNCI Cancer Spectrum, Vol. 7, Núm. 6

  5. Radiation Therapy for Metastatic Lung Cancer: Bone Metastasis and Metastatic Spinal Cord Compression

    Medical Radiology (Springer Science and Business Media Deutschland GmbH), pp. 779-793

  6. Radiobiological Meta-Analysis of the Response of Prostate Cancer to Different Fractionations: Evaluation of the Linear–Quadratic Response at Large Doses and the Effect of Risk and ADT

    Cancers, Vol. 15, Núm. 14

  7. Radiogenomics in lung cancer: Where are we?

    Lung Cancer, Vol. 176, pp. 56-74

  8. Variation of the relative biological effectiveness with fractionation in proton therapy: Analysis of prostate cancer response

    Medical Physics, Vol. 50, Núm. 11, pp. 7304-7312

2022

  1. Development of castration resistance in prostate cancer patients treated with luteinizing hormone-releasing hormone analogues (LHRHa): results of the ANARESISTANCE study

    World Journal of Urology, Vol. 40, Núm. 10, pp. 2459-2466

  2. Effect of LHRH analogs on lower urinary tract symptoms associated with advanced prostate cancer in real clinical practice: ANALUTS study

    Neurourology and Urodynamics, Vol. 41, Núm. 8, pp. 1824-1833

  3. High weekly integral dose and larger fraction size increase risk of fatigue and worsening of functional outcomes following radiotherapy for localized prostate cancer

    Frontiers in Oncology, Vol. 12

  4. Meta-GWAS identifies the heritability of acute radiation-induced toxicities in head and neck cancer

    Radiotherapy and Oncology, Vol. 176, pp. 138-148

  5. No Association Between Polygenic Risk Scores for Cancer and Development of Radiation Therapy Toxicity

    International Journal of Radiation Oncology Biology Physics, Vol. 114, Núm. 3, pp. 494-501

  6. Quality indicators and excellence requirements for a multidisciplinary lung cancer tumor board by the Spanish Lung Cancer Group

    Clinical and Translational Oncology, Vol. 24, Núm. 3, pp. 446-459

  7. RENORT: a project to analyze patterns of care in radiation oncology in Spain

    Clinical and Translational Oncology, Vol. 24, Núm. 7, pp. 1322-1332

  8. Treatment time and circadian genotype interact to influence radiotherapy side-effects. A prospective European validation study using the REQUITE cohort

    eBioMedicine, Vol. 84

  9. Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer

    Radiotherapy and Oncology, Vol. 168, pp. 75-82

2021

  1. Evaluation of indirect damage and damage saturation effects in dose–response curves of hypofractionated radiotherapy of early-stage NSCLC and brain metastases

    Radiotherapy and Oncology, Vol. 161, pp. 1-8